<DOC>
	<DOCNO>NCT01326026</DOCNO>
	<brief_summary>This trial conduct Europe United States America ( USA ) . The aim trial compare efficacy safety NN1250 ( insulin degludec ( IDeg ) ) daily insulin naïve subject type 2 diabetes mellitus titrate use two different self-titration algorithm ( dose individually adjust ) combination metformin .</brief_summary>
	<brief_title>Comparing Efficacy Safety NN1250 Once Daily When Titrated Using 2 Different Algorithms Insulin naïve Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 2 diabetes ( diagnose clinically ) least 24 week prior randomisation ( Visit 2 ) Current treatment : metformin monotherapy metformin combination 1 2 OADs include insulin secretagogue ( sulfonylurea glinide ) , dipeptidyl peptidase IV ( DPPIV ) inhibitor , alphaglucosidase inhibitor , thiazolidinediones ( TZDs ) unchanged dose least 12 week prior randomisation ( Visit 2 ) metformin : alone combination ( include fix combination ) must least 1000 mg daily HbA1c 7.010.0 % ( inclusive ) central laboratory analysis BMI ( Body Mass Index ) high 45.0 kg/m^2 Treatment glucagonlike peptide 1 ( GLP1 ) receptor agonist within last 12 week prior Visit 2 Suffer life threaten disease ( e.g . cancer ) Females childbearing potential pregnant ( determined central laboratory betahuman chorionic gonadotropin ( betahCG ) , breast feeding intend become pregnant use adequate contraceptive method ( adequate contraceptive method require law practise [ Germany , adequate contraceptive method : implant , injectables , combine oral contraceptive , hormonal IUD , sexual abstinence vasectomise partner ] )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>